Objective To explore the value of fascial tail sign at MR images in the detection of nodular fasciitis (NF). Methods A retrospective analysis of MR images was performed in 19 patients with pathologically proven NF of the soft tissue and 53 patients with a variety of other fibrous-predominant tumors. MR manifestations of all cases were reviewed by two experienced musculoskeletal radiologists using a single blind method. The presence of fascial tail on MR images were evaluated. ROC was used to assess the value of fascial tail sign in the detection of NF. Sensitivity, specificity, Youden index and area under ROC curve were calculated. The association between the presence of fascial tail sign on MRI and pathological classification of NF was analyzed by Pearson chi-square test for independence . Results Fascial tail was present in 17 cases (89.5%) of the study group and in 6 cases (11.3%) of the control group, respectively, yielding a sensitivity of 89.5%, a specificity of 88.7%, a Youden index of 0.782 and an area under ROC curve of 0.891. The fascial tail sign was significantly associated with NF (c2=39.294,P<0.05,r=0.594). Conclusions Fascial tail sign at MRI is a moderately specific and sensitive for the diagnosis of NF relative to fibrous-predominant tumors. It can be used in differentiate between NF and aggressive soft tissue tumors.

Objective To systematically review the efficacy and safety of denosemab and zoledronic acid in patients with solid tumors bone metastases and multiple myeloma.Methods Pubmed,Embase,Cochrane Library,Web of Science,CNKI,WanFang Data and VIP databases were electronically searched for randomized controlled trials(RCTs)related to denosemab and zoledronic acid in the solid tumors bone metastases and multiple myeloma from inception to November 21,2023.Two reviewers independently screened literature,extracted data and assessed the risk of bias of included studies,and Meta-analysis was performed by using RevMan 5.3 software.Results A total of 5 RCTs,involving 8 957 patients were included.The results of Meta-analysis showed that denosumab was effective in delaying the time to first bone-related event(SRE)(HR=0.85,95％CI 0.80 to 0.92,P＜0.001)and the time to first and subsequent SRE time(HR=0.87,95％CI 0.79 to 0.96,P=0.004)were superior to zoledronic acid.Denosumab had lower incidence of nephrotoxicity(RR=0.70,95％CI 0.58 to 0.85,P＜0.001),acute phase response(RR=0.46,95％CI 0.40 to 0.51,P＜0.001),anemia(RR=0.91,95％CI 0.85 to 0.98,P=0.008)and appetite decreased/anorexia(RR=0.89,95％CI 0.81 to 0.98,P=0.02),but the incidence of hypocalcemia was higher(RR=1.72,95％CI 1.49 to 1.99,P＜0.001).There were no significant differences between denosumab and zoledronic acid in terms of overall survival,time to disease progression,incidence of adverse events and serious adverse events(P＞0.05).Conclusion Current evidence shows that compared with zoledronic acid,denosemab can significantly delay SREs induced by solid tumors bone metastases and multiple myeloma.In terms of safety,the risk of denosemab-induced nephrotoxicity,acute phase reactions,anemia and decreased appetite/anorexia are lower,but the risk of denosemab-induced hypocalcemia is higher.